Biologics targeting upstream alarmins (e.g., IL-33/TSLP) and downstream cytokines (e.g., IL-1β, IL-6) aim to disrupt inflammatory redundancy; cell-based and regenerative approaches represent long-term precision strategies for emphysema. This evidence concerns the gene IL6 and pulmonary emphysema.